Value-Based Care

How Does the ACCESS Program Redefine Pharmacy Practice?
Management & Administration How Does the ACCESS Program Redefine Pharmacy Practice?

The NCPA-led initiative represents a monumental shift in the professional evolution of pharmacists, establishing them as recognized members of the primary chronic care team. This change is not merely cosmetic; it signals a fundamental transition from a volume-based dispensing model to a value-based

How Can AI Close the Last Mile Gap in Value-Based Care?
Tech & Innovation How Can AI Close the Last Mile Gap in Value-Based Care?

Success in value-based care requires bridging the gap between identifying patient risks and executing clinical interventions through real-time actionable intelligence. Before beginning, ensure the medical practice has full access to an integrated electronic health record system capable of

Will Your UHC Medicare Plan Still Work at Sarasota Memorial?
Management & Administration Will Your UHC Medicare Plan Still Work at Sarasota Memorial?

The Impending Network Shift: Health Access in Sarasota The dispute highlights a growing divide over how insurance companies manage prior authorizations and the impact these decisions have on hospital reimbursement cycles. This friction is currently coming to a head in Southwest Florida, where the

Is Value-Based Care a Healthcare Solution or a Failed Experiment?
Management & Administration Is Value-Based Care a Healthcare Solution or a Failed Experiment?

Some medical professionals argue that current healthcare metrics create perverse incentives, rewarding providers for documenting patients as sicker on paper rather than actually improving their health status. This fundamental tension defines the modern landscape as the American medical system

How Will the 2027 Medicare Fee Rule Impact Physician Pay?
Management & Administration How Will the 2027 Medicare Fee Rule Impact Physician Pay?

Starting in 2027, remote patient monitoring services will be restricted to established patients and require a separately reportable initiating visit for reimbursement. This specific regulatory adjustment is just one facet of the massive 2,400-page 2027 Medicare Physician Fee Schedule, a document

Payers Prioritize Clinical Evidence Over Drug Approval Volume
Management & Administration Payers Prioritize Clinical Evidence Over Drug Approval Volume

The existence of a biosimilar within a six-month window can prevent a health plan from entering into a long-term contract with a brand-name manufacturer. This strategic hesitation underscores a broader shift in the pharmaceutical industry where the velocity of regulatory approvals is no longer the

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later